<?xml version="1.0" encoding="UTF-16"?>
<leg xml:space="preserve" billnum="SB0083" sponsor="Evan J. Vickers" designation="SB" otherSponsor="Logan J. Monson" otherHouse="House" sess="2026GS" fileno="2026FL0905" date="1/6/2026 12:01:803" printDate="02-06 16:51" subVer="0" minVer="0" office="LEGISLATIVE GENERAL COUNSEL" actionDate="" impact="code"><info><nextbuid>3</nextbuid><aminfo anum="0" effdate="05/06/2026"><seclist><sect action="A" src="code" buid="1" uid="C58-37-S4_2026050620260506" fromuid="C58-37-S4_2025050720250507" sort="58 37 00040020260506" mtype="section" effdate="05/06/2026">58-37-4</sect><sect src="uncod" untype="effdate" buid="2" uid="EF0000" sort="UZEFF" mtype="uncod" effdate="05/06/2026"/></seclist></aminfo></info><tbox><sinfo><nextpairid>0</nextpairid></sinfo><st numlevel="1" lineno="1" slineno="0-1">Controlled Substance Scheduling Amendments</st><sessionhead>2026 GENERAL SESSION</sessionhead><statehead>STATE OF UTAH</statehead><sponsorhead>Chief Sponsor: Evan J. Vickers</sponsorhead><otherSponsorhead>House Sponsor: Logan J. Monson</otherSponsorhead></tbox><lt numlevel="1" lineno="2" slineno="0-2"><lthead lineno="3">LONG TITLE</lthead><gdhead lineno="4">General Description:</gdhead><gd numlevel="1" lineno="5" slineno="0-5">This bill amends provisions related to controlled substance scheduling.</gd><hphead lineno="6">Highlighted Provisions:</hphead><hp numlevel="1" lineno="7" slineno="0-7">This bill:<hl numlevel="1" lineno="8" slineno="0-8" level="1">allows for the automatic rescheduling of a pharmaceutical composition of a schedule I <ln numlevel="1" lineno="9" slineno="0-9"/>controlled substance if the pharmaceutical composition is rescheduled under federal law. </hl></hp><moni numlevel="1" lineno="10" slineno="0-10" display="none">Money Appropriated in this Bill:</moni><moniNone lineno="11">None</moniNone><oc numlevel="1" lineno="12" slineno="0-12">Other Special Clauses:</oc><ocNone lineno="13">None</ocNone><sa numlevel="1" lineno="14" slineno="0-14">Utah Code Sections Affected:<saamd numlevel="1" lineno="15" slineno="0-15"><snhead>AMENDS:</snhead><sn num="58-37-4" src="code" uid="C58-37-S4_2026050620260506" buid="1" sort="58 37 00040020260506" numlevel="1" lineno="16" slineno="0-16"><bold>58-37-4</bold>, as last amended by Laws of Utah 2025, Chapter 216</sn></saamd></sa></lt><enacthead lineno="17"/><enact numlevel="1" lineno="18" slineno="0-18">Be it enacted by the Legislature of the state of Utah:</enact><bdy><bsec buid="1" num="58-37-4" type="amend" src="code" uid="C58-37-S4_2026050620260506" sort="58 37 00040020260506" numlevel="1" lineno="19" slineno="1-1" sn="1"><section number="58-37-4" numlevel="1" lineno="20" slineno="1-2" type="amend"><secline lineno="19">Section 1. Section <bold>58-37-4</bold> is amended to read:</secline><catline lineno="20"><bold>58-37-4<parens/>. Schedules of controlled substances -- Schedules I through V -- Findings <ln numlevel="1" lineno="21" slineno="1-3"/>required -- Specific substances included in schedules.</bold></catline><subsection ssid="1-null-1" dnum="1-o" numlevel="1" lineno="22" slineno="1-4" level="1" placement="noreturn"><display>(1)</display>There are established five schedules of controlled substances known as Schedules I, II, <ln numlevel="1" lineno="23" slineno="1-5"/>III, IV, and V which consist of substances listed in this section.</subsection><subsection ssid="1-null-2" dnum="2-o" numlevel="1" lineno="24" slineno="1-6" level="1"><display>(2)</display>Schedules I, II, III, IV, and V consist of the following drugs or other substances by the <ln numlevel="1" lineno="25" slineno="1-7"/>official name, common or usual name, chemical name, or brand name designated:<subsection ssid="1-null-3" dnum="a-o" numlevel="1" lineno="26" slineno="1-8" level="2"><display>(a)</display><amend anum="0" ea="amend" pairid="6" groupid="5" style="1" owner="jchristopherson" level="1" amendtag="both">Except as provided in Subsection <xref depth="4" refnumber="58-37-4(3)">(3)</xref>, </amend>Schedule I:<subsection ssid="1-null-4" dnum="i-o" numlevel="1" lineno="27" slineno="1-9" level="3"><display>(i)</display>Unless specifically excepted or unless listed in another schedule, any of the <ln numlevel="1" lineno="28" slineno="1-10"/>following opiates, including their isomers, esters, ethers, salts, and salts of <ln numlevel="1" lineno="29" slineno="1-11"/>isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and <ln numlevel="1" lineno="30" slineno="1-12"/>salts is possible within the specific chemical designation:<subsection ssid="1-null-5" dnum="A-o" numlevel="1" lineno="31" slineno="1-13" level="4"><display>(A)</display>Acetyl-alpha-methylfentanyl <ln numlevel="1" lineno="32" slineno="1-14"/>(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);</subsection><subsection ssid="1-null-6" dnum="B-o" numlevel="1" lineno="33" slineno="1-15" level="4"><display>(B)</display>Acetyl fentanyl:  (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);</subsection><subsection ssid="1-null-7" dnum="C-o" numlevel="1" lineno="34" slineno="1-16" level="4"><display>(C)</display>Acetylmethadol;</subsection><subsection ssid="1-null-8" dnum="D-o" numlevel="1" lineno="35" slineno="1-17" level="4"><display>(D)</display>Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);</subsection><subsection ssid="1-null-9" dnum="E-o" numlevel="1" lineno="36" slineno="1-18" level="4"><display>(E)</display>Allylprodine;</subsection><subsection ssid="1-null-10" dnum="F-o" numlevel="1" lineno="37" slineno="1-19" level="4"><display>(F)</display>Alphacetylmethadol, except levo-alphacetylmethadol also known as <ln numlevel="1" lineno="38" slineno="1-20"/>levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;</subsection><subsection ssid="1-null-11" dnum="G-o" numlevel="1" lineno="39" slineno="1-21" level="4"><display>(G)</display>Alphameprodine;</subsection><subsection ssid="1-null-12" dnum="H-o" numlevel="1" lineno="40" slineno="1-22" level="4"><display>(H)</display>Alphamethadol;</subsection><subsection ssid="1-null-13" dnum="I-o" numlevel="1" lineno="41" slineno="1-23" level="4"><display>(I)</display>Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] <ln numlevel="1" lineno="42" slineno="1-24"/>propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);</subsection><subsection ssid="1-null-14" dnum="J-o" numlevel="1" lineno="43" slineno="1-25" level="4"><display>(J)</display>Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- <ln numlevel="1" lineno="44" slineno="1-26"/>piperidinyl]-N-phenylpropanamide);</subsection><subsection ssid="1-null-15" dnum="K-o" numlevel="1" lineno="45" slineno="1-27" level="4"><display>(K)</display>Benzylpiperazine;</subsection><subsection ssid="1-null-16" dnum="L-o" numlevel="1" lineno="46" slineno="1-28" level="4"><display>(L)</display>Benzethidine;</subsection><subsection ssid="1-null-17" dnum="M-o" numlevel="1" lineno="47" slineno="1-29" level="4"><display>(M)</display>Betacetylmethadol;</subsection><subsection ssid="1-null-18" dnum="N-o" numlevel="1" lineno="48" slineno="1-30" level="4"><display>(N)</display>Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- <ln numlevel="1" lineno="49" slineno="1-31"/>piperidinyl]-N-phenylpropanamide);</subsection><subsection ssid="1-null-19" dnum="O-o" numlevel="1" lineno="50" slineno="1-32" level="4"><display>(O)</display>Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- <ln numlevel="1" lineno="51" slineno="1-33"/>phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;</subsection><subsection ssid="1-null-20" dnum="P-o" numlevel="1" lineno="52" slineno="1-34" level="4"><display>(P)</display>Betameprodine;</subsection><subsection ssid="1-null-21" dnum="Q-o" numlevel="1" lineno="53" slineno="1-35" level="4"><display>(Q)</display>Betamethadol;</subsection><subsection ssid="1-null-22" dnum="R-o" numlevel="1" lineno="54" slineno="1-36" level="4"><display>(R)</display>Betaprodine;</subsection><subsection ssid="1-null-23" dnum="S-o" numlevel="1" lineno="55" slineno="1-37" level="4"><display>(S)</display>Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);</subsection><subsection ssid="1-null-24" dnum="T-o" numlevel="1" lineno="56" slineno="1-38" level="4"><display>(T)</display>Clonitazene;</subsection><subsection ssid="1-null-25" dnum="U-o" numlevel="1" lineno="57" slineno="1-39" level="4"><display>(U)</display>Cyclopropyl fentanyl <ln numlevel="1" lineno="58" slineno="1-40"/>(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);</subsection><subsection ssid="1-null-26" dnum="V-o" numlevel="1" lineno="59" slineno="1-41" level="4"><display>(V)</display>Dextromoramide;</subsection><subsection ssid="1-null-27" dnum="W-o" numlevel="1" lineno="60" slineno="1-42" level="4"><display>(W)</display>Diampromide;</subsection><subsection ssid="1-null-28" dnum="X-o" numlevel="1" lineno="61" slineno="1-43" level="4"><display>(X)</display>Diethylthiambutene;</subsection><subsection ssid="1-null-29" dnum="Y-o" numlevel="1" lineno="62" slineno="1-44" level="4"><display>(Y)</display>Difenoxin;</subsection><subsection ssid="1-null-30" dnum="Z-o" numlevel="1" lineno="63" slineno="1-45" level="4"><display>(Z)</display>Dimenoxadol;</subsection><subsection ssid="1-null-31" dnum="AA-o" numlevel="1" lineno="64" slineno="1-46" level="4"><display>(AA)</display>Dimepheptanol;</subsection><subsection ssid="1-null-32" dnum="BB-o" numlevel="1" lineno="65" slineno="1-47" level="4"><display>(BB)</display>Dimethylthiambutene;</subsection><subsection ssid="1-null-33" dnum="CC-o" numlevel="1" lineno="66" slineno="1-48" level="4"><display>(CC)</display>Dioxaphetyl butyrate;</subsection><subsection ssid="1-null-34" dnum="DD-o" numlevel="1" lineno="67" slineno="1-49" level="4"><display>(DD)</display>Dipipanone;</subsection><subsection ssid="1-null-35" dnum="EE-o" numlevel="1" lineno="68" slineno="1-50" level="4"><display>(EE)</display>Ethylmethylthiambutene;</subsection><subsection ssid="1-null-36" dnum="FF-o" numlevel="1" lineno="69" slineno="1-51" level="4"><display>(FF)</display>Etizolam  <ln numlevel="1" lineno="70" slineno="1-52"/>(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);</subsection><subsection ssid="1-null-37" dnum="GG-o" numlevel="1" lineno="71" slineno="1-53" level="4"><display>(GG)</display>Etonitazene;</subsection><subsection ssid="1-null-38" dnum="HH-o" numlevel="1" lineno="72" slineno="1-54" level="4"><display>(HH)</display>Etoxeridine;</subsection><subsection ssid="1-null-39" dnum="II-o" numlevel="1" lineno="73" slineno="1-55" level="4"><display>(II)</display>Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] <ln numlevel="1" lineno="74" slineno="1-56"/>furan-2-carboxamide);</subsection><subsection ssid="1-null-40" dnum="JJ-o" numlevel="1" lineno="75" slineno="1-57" level="4"><display>(JJ)</display>Furethidine;</subsection><subsection ssid="1-null-41" dnum="KK-o" numlevel="1" lineno="76" slineno="1-58" level="4"><display>(KK)</display>Hydroxypethidine;</subsection><subsection ssid="1-null-42" dnum="LL-o" numlevel="1" lineno="77" slineno="1-59" level="4"><display>(LL)</display>Ketobemidone;</subsection><subsection ssid="1-null-43" dnum="MM-o" numlevel="1" lineno="78" slineno="1-60" level="4"><display>(MM)</display>Levomoramide;</subsection><subsection ssid="1-null-44" dnum="NN-o" numlevel="1" lineno="79" slineno="1-61" level="4"><display>(NN)</display>Levophenacylmorphan;</subsection><subsection ssid="1-null-45" dnum="OO-o" numlevel="1" lineno="80" slineno="1-62" level="4"><display>(OO)</display>Methoxyacetyl fentanyl <ln numlevel="1" lineno="81" slineno="1-63"/>(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);</subsection><subsection ssid="1-null-46" dnum="PP-o" numlevel="1" lineno="82" slineno="1-64" level="4"><display>(PP)</display>Morpheridine;</subsection><subsection ssid="1-null-47" dnum="QQ-o" numlevel="1" lineno="83" slineno="1-65" level="4"><display>(QQ)</display>MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);</subsection><subsection ssid="1-null-48" dnum="RR-o" numlevel="1" lineno="84" slineno="1-66" level="4"><display>(RR)</display>Noracymethadol;</subsection><subsection ssid="1-null-49" dnum="SS-o" numlevel="1" lineno="85" slineno="1-67" level="4"><display>(SS)</display>Norlevorphanol;</subsection><subsection ssid="1-null-50" dnum="TT-o" numlevel="1" lineno="86" slineno="1-68" level="4"><display>(TT)</display>Normethadone;</subsection><subsection ssid="1-null-51" dnum="UU-o" numlevel="1" lineno="87" slineno="1-69" level="4"><display>(UU)</display>Norpipanone;</subsection><subsection ssid="1-null-52" dnum="VV-o" numlevel="1" lineno="88" slineno="1-70" level="4"><display>(VV)</display>Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] <ln numlevel="1" lineno="89" slineno="1-71"/>propanamide);</subsection><subsection ssid="1-null-53" dnum="WW-o" numlevel="1" lineno="90" slineno="1-72" level="4"><display>(WW)</display>Para-fluoroisobutyryl fentanyl <ln numlevel="1" lineno="91" slineno="1-73"/>(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);</subsection><subsection ssid="1-null-54" dnum="XX-o" numlevel="1" lineno="92" slineno="1-74" level="4"><display>(XX)</display>PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);</subsection><subsection ssid="1-null-55" dnum="YY-o" numlevel="1" lineno="93" slineno="1-75" level="4"><display>(YY)</display>Phenadoxone;</subsection><subsection ssid="1-null-56" dnum="ZZ-o" numlevel="1" lineno="94" slineno="1-76" level="4"><display>(ZZ)</display>Phenampromide;</subsection><subsection ssid="1-null-57" dnum="AAA-o" numlevel="1" lineno="95" slineno="1-77" level="4"><display>(AAA)</display>Phenibut;</subsection><subsection ssid="1-null-58" dnum="BBB-o" numlevel="1" lineno="96" slineno="1-78" level="4"><display>(BBB)</display>Phenomorphan;</subsection><subsection ssid="1-null-59" dnum="CCC-o" numlevel="1" lineno="97" slineno="1-79" level="4"><display>(CCC)</display>Phenoperidine;</subsection><subsection ssid="1-null-60" dnum="DDD-o" numlevel="1" lineno="98" slineno="1-80" level="4"><display>(DDD)</display>Piritramide;</subsection><subsection ssid="1-null-61" dnum="EEE-o" numlevel="1" lineno="99" slineno="1-81" level="4"><display>(EEE)</display>Proheptazine;</subsection><subsection ssid="1-null-62" dnum="FFF-o" numlevel="1" lineno="100" slineno="1-82" level="4"><display>(FFF)</display>Properidine;</subsection><subsection ssid="1-null-63" dnum="GGG-o" numlevel="1" lineno="101" slineno="1-83" level="4"><display>(GGG)</display>Propiram;</subsection><subsection ssid="1-null-64" dnum="HHH-o" numlevel="1" lineno="102" slineno="1-84" level="4"><display>(HHH)</display>Racemoramide;</subsection><subsection ssid="1-null-65" dnum="III-o" numlevel="1" lineno="103" slineno="1-85" level="4"><display>(III)</display>Tetrahydrofuran fentanyl <ln numlevel="1" lineno="104" slineno="1-86"/>(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);</subsection><subsection ssid="1-null-66" dnum="JJJ-o" numlevel="1" lineno="105" slineno="1-87" level="4"><display>(JJJ)</display>Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;</subsection><subsection ssid="1-null-67" dnum="KKK-o" numlevel="1" lineno="106" slineno="1-88" level="4"><display>(KKK)</display>Tianeptine;</subsection><subsection ssid="1-null-68" dnum="LLL-o" numlevel="1" lineno="107" slineno="1-89" level="4"><display>(LLL)</display>Tilidine;</subsection><subsection ssid="1-null-69" dnum="MMM-o" numlevel="1" lineno="108" slineno="1-90" level="4"><display>(MMM)</display>Trimeperidine;</subsection><subsection ssid="1-null-70" dnum="NNN-o" numlevel="1" lineno="109" slineno="1-91" level="4"><display>(NNN)</display>3-methylfentanyl, including the optical and geometric isomers <ln numlevel="1" lineno="110" slineno="1-92"/>(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);</subsection><subsection ssid="1-null-71" dnum="OOO-o" numlevel="1" lineno="111" slineno="1-93" level="4"><display>(OOO)</display>3-methylthiofentanyl <ln numlevel="1" lineno="112" slineno="1-94"/>(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);</subsection><subsection ssid="1-null-72" dnum="PPP-o" numlevel="1" lineno="113" slineno="1-95" level="4"><display>(PPP)</display>3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also <ln numlevel="1" lineno="114" slineno="1-96"/>known as U-47700; and</subsection><subsection ssid="1-null-73" dnum="QQQ-o" numlevel="1" lineno="115" slineno="1-97" level="4"><display>(QQQ)</display>4-cyano CUMYL-BUTINACA.</subsection></subsection><subsection ssid="1-null-74" dnum="ii-o" numlevel="1" lineno="116" slineno="1-98" level="3"><display>(ii)</display>Unless specifically excepted or unless listed in another schedule, any of the <ln numlevel="1" lineno="117" slineno="1-99"/>following opium derivatives, their salts, isomers, and salts of isomers when the <ln numlevel="1" lineno="118" slineno="1-100"/>existence of the salts, isomers, and salts of isomers is possible within the specific <ln numlevel="1" lineno="119" slineno="1-101"/>chemical designation:<subsection ssid="1-null-75" dnum="A-o" numlevel="1" lineno="120" slineno="1-102" level="4"><display>(A)</display>Acetorphine;</subsection><subsection ssid="1-null-76" dnum="B-o" numlevel="1" lineno="121" slineno="1-103" level="4"><display>(B)</display>Acetyldihydrocodeine;</subsection><subsection ssid="1-null-77" dnum="C-o" numlevel="1" lineno="122" slineno="1-104" level="4"><display>(C)</display>Benzylmorphine;</subsection><subsection ssid="1-null-78" dnum="D-o" numlevel="1" lineno="123" slineno="1-105" level="4"><display>(D)</display>Codeine methylbromide;</subsection><subsection ssid="1-null-79" dnum="E-o" numlevel="1" lineno="124" slineno="1-106" level="4"><display>(E)</display>Codeine-N-Oxide;</subsection><subsection ssid="1-null-80" dnum="F-o" numlevel="1" lineno="125" slineno="1-107" level="4"><display>(F)</display>Cyprenorphine;</subsection><subsection ssid="1-null-81" dnum="G-o" numlevel="1" lineno="126" slineno="1-108" level="4"><display>(G)</display>Desomorphine;</subsection><subsection ssid="1-null-82" dnum="H-o" numlevel="1" lineno="127" slineno="1-109" level="4"><display>(H)</display>Dihydromorphine;</subsection><subsection ssid="1-null-83" dnum="I-o" numlevel="1" lineno="128" slineno="1-110" level="4"><display>(I)</display>Drotebanol;</subsection><subsection ssid="1-null-84" dnum="J-o" numlevel="1" lineno="129" slineno="1-111" level="4"><display>(J)</display>Etorphine (except hydrochloride salt);</subsection><subsection ssid="1-null-85" dnum="K-o" numlevel="1" lineno="130" slineno="1-112" level="4"><display>(K)</display>Heroin;</subsection><subsection ssid="1-null-86" dnum="L-o" numlevel="1" lineno="131" slineno="1-113" level="4"><display>(L)</display>Hydromorphinol;</subsection><subsection ssid="1-null-87" dnum="M-o" numlevel="1" lineno="132" slineno="1-114" level="4"><display>(M)</display>Methyldesorphine;</subsection><subsection ssid="1-null-88" dnum="N-o" numlevel="1" lineno="133" slineno="1-115" level="4"><display>(N)</display>Methylhydromorphine;</subsection><subsection ssid="1-null-89" dnum="O-o" numlevel="1" lineno="134" slineno="1-116" level="4"><display>(O)</display>Morphine methylbromide;</subsection><subsection ssid="1-null-90" dnum="P-o" numlevel="1" lineno="135" slineno="1-117" level="4"><display>(P)</display>Morphine methylsulfonate;</subsection><subsection ssid="1-null-91" dnum="Q-o" numlevel="1" lineno="136" slineno="1-118" level="4"><display>(Q)</display>Morphine-N-Oxide;</subsection><subsection ssid="1-null-92" dnum="R-o" numlevel="1" lineno="137" slineno="1-119" level="4"><display>(R)</display>Myrophine;</subsection><subsection ssid="1-null-93" dnum="S-o" numlevel="1" lineno="138" slineno="1-120" level="4"><display>(S)</display>Nicocodeine;</subsection><subsection ssid="1-null-94" dnum="T-o" numlevel="1" lineno="139" slineno="1-121" level="4"><display>(T)</display>Nicomorphine;</subsection><subsection ssid="1-null-95" dnum="U-o" numlevel="1" lineno="140" slineno="1-122" level="4"><display>(U)</display>Normorphine;</subsection><subsection ssid="1-null-96" dnum="V-o" numlevel="1" lineno="141" slineno="1-123" level="4"><display>(V)</display>Pholcodine; and</subsection><subsection ssid="1-null-97" dnum="W-o" numlevel="1" lineno="142" slineno="1-124" level="4"><display>(W)</display>Thebacon.</subsection></subsection><subsection ssid="1-null-98" dnum="iii-o" numlevel="1" lineno="143" slineno="1-125" level="3"><display>(iii)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="144" slineno="1-126"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="145" slineno="1-127"/>hallucinogenic substances, or which contains any of their salts, isomers, and salts <ln numlevel="1" lineno="146" slineno="1-128"/>of isomers when the existence of the salts, isomers, and salts of isomers is possible <ln numlevel="1" lineno="147" slineno="1-129"/>within the specific chemical designation; as used in this Subsection <xref depth="4" refnumber="58-37-4(2)(a)(iii)">(2)(a)(iii)</xref> <ln numlevel="1" lineno="148" slineno="1-130"/>only, "isomer" includes the optical, position, and geometric isomers:<subsection ssid="1-null-99" dnum="A-o" numlevel="1" lineno="149" slineno="1-131" level="4"><display>(A)</display>Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; <char set="8" char="1"/><ln numlevel="1" lineno="150" slineno="1-132"/>-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; <char set="8" char="1"/>-ET; and AET;</subsection><subsection ssid="1-null-100" dnum="B-o" numlevel="1" lineno="151" slineno="1-133" level="4"><display>(B)</display>4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: <ln numlevel="1" lineno="152" slineno="1-134"/>4-bromo-2,5-dimethoxy-<char set="8" char="1"/>-methylphenethylamine; 4-bromo-2,5-DMA;</subsection><subsection ssid="1-null-101" dnum="C-o" numlevel="1" lineno="153" slineno="1-135" level="4"><display>(C)</display>4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: <ln numlevel="1" lineno="154" slineno="1-136"/>2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; <ln numlevel="1" lineno="155" slineno="1-137"/>2C-B, Nexus;</subsection><subsection ssid="1-null-102" dnum="D-o" numlevel="1" lineno="156" slineno="1-138" level="4"><display>(D)</display>2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-<char set="8" char="1"/><ln numlevel="1" lineno="157" slineno="1-139"/>-methylphenethylamine; 2,5-DMA;</subsection><subsection ssid="1-null-103" dnum="E-o" numlevel="1" lineno="158" slineno="1-140" level="4"><display>(E)</display>2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;</subsection><subsection ssid="1-null-104" dnum="F-o" numlevel="1" lineno="159" slineno="1-141" level="4"><display>(F)</display>4-methoxyamphetamine, some trade or other names: 4-methoxy-<char set="8" char="1"/><ln numlevel="1" lineno="160" slineno="1-142"/>-methylphenethylamine; paramethoxyamphetamine, PMA;</subsection><subsection ssid="1-null-105" dnum="G-o" numlevel="1" lineno="161" slineno="1-143" level="4"><display>(G)</display>5-methoxy-3,4-methylenedioxyamphetamine;</subsection><subsection ssid="1-null-106" dnum="H-o" numlevel="1" lineno="162" slineno="1-144" level="4"><display>(H)</display>4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: <ln numlevel="1" lineno="163" slineno="1-145"/>4-methyl-2,5-dimethoxy-<char set="8" char="1"/>-methylphenethylamine; "DOM"; and "STP";</subsection><subsection ssid="1-null-107" dnum="I-o" numlevel="1" lineno="164" slineno="1-146" level="4"><display>(I)</display>3,4-methylenedioxy amphetamine;</subsection><subsection ssid="1-null-108" dnum="J-o" numlevel="1" lineno="165" slineno="1-147" level="4"><display>(J)</display>3,4-methylenedioxymethamphetamine (MDMA);</subsection><subsection ssid="1-null-109" dnum="K-o" numlevel="1" lineno="166" slineno="1-148" level="4"><display>(K)</display>3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- <ln numlevel="1" lineno="167" slineno="1-149"/>alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, <ln numlevel="1" lineno="168" slineno="1-150"/>MDEA;</subsection><subsection ssid="1-null-110" dnum="L-o" numlevel="1" lineno="169" slineno="1-151" level="4"><display>(L)</display>N-hydroxy-3,4-methylenedioxyamphetamine, also known as <ln numlevel="1" lineno="170" slineno="1-152"/>N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy <ln numlevel="1" lineno="171" slineno="1-153"/>MDA;</subsection><subsection ssid="1-null-111" dnum="M-o" numlevel="1" lineno="172" slineno="1-154" level="4"><display>(M)</display>3,4,5-trimethoxy amphetamine;</subsection><subsection ssid="1-null-112" dnum="N-o" numlevel="1" lineno="173" slineno="1-155" level="4"><display>(N)</display>Bufotenine, some trade and other names: 3-(<char set="8" char="3"/><ln numlevel="1" lineno="174" slineno="1-156"/>-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; <ln numlevel="1" lineno="175" slineno="1-157"/>N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;</subsection><subsection ssid="1-null-113" dnum="O-o" numlevel="1" lineno="176" slineno="1-158" level="4"><display>(O)</display>Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;</subsection><subsection ssid="1-null-114" dnum="P-o" numlevel="1" lineno="177" slineno="1-159" level="4"><display>(P)</display>Dimethyltryptamine, some trade or other names: DMT;</subsection><subsection ssid="1-null-115" dnum="Q-o" numlevel="1" lineno="178" slineno="1-160" level="4"><display>(Q)</display>Ibogaine, some trade and other names: 7-Ethyl-6,6<char set="8" char="3"/><ln numlevel="1" lineno="179" slineno="1-161"/>,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] <ln numlevel="1" lineno="180" slineno="1-162"/>azepino [5,4-b] indole; Tabernanthe iboga;</subsection><subsection ssid="1-null-116" dnum="R-o" numlevel="1" lineno="181" slineno="1-163" level="4"><display>(R)</display>Lysergic acid diethylamide;</subsection><subsection ssid="1-null-117" dnum="S-o" numlevel="1" lineno="182" slineno="1-164" level="4"><display>(S)</display>Marijuana;</subsection><subsection ssid="1-null-118" dnum="T-o" numlevel="1" lineno="183" slineno="1-165" level="4"><display>(T)</display>Mescaline;</subsection><subsection ssid="1-null-119" dnum="U-o" numlevel="1" lineno="184" slineno="1-166" level="4"><display>(U)</display>Parahexyl, some trade or other names: <ln numlevel="1" lineno="185" slineno="1-167"/>3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; <ln numlevel="1" lineno="186" slineno="1-168"/>Synhexyl;</subsection><subsection ssid="1-null-120" dnum="V-o" numlevel="1" lineno="187" slineno="1-169" level="4"><display>(V)</display>Peyote, meaning all parts of the plant presently classified botanically as <ln numlevel="1" lineno="188" slineno="1-170"/>Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any <ln numlevel="1" lineno="189" slineno="1-171"/>extract from any part of such plant, and every compound, manufacture, salts, <ln numlevel="1" lineno="190" slineno="1-172"/>derivative, mixture, or preparation of such plant, its seeds or extracts <ln numlevel="1" lineno="191" slineno="1-173"/>(Interprets 21 USC 812(c), Schedule I(c) (12));</subsection><subsection ssid="1-null-121" dnum="W-o" numlevel="1" lineno="192" slineno="1-174" level="4"><display>(W)</display>N-ethyl-3-piperidyl benzilate;</subsection><subsection ssid="1-null-122" dnum="X-o" numlevel="1" lineno="193" slineno="1-175" level="4"><display>(X)</display>N-methyl-3-piperidyl benzilate;</subsection><subsection ssid="1-null-123" dnum="Y-o" numlevel="1" lineno="194" slineno="1-176" level="4"><display>(Y)</display>Psilocybin;</subsection><subsection ssid="1-null-124" dnum="Z-o" numlevel="1" lineno="195" slineno="1-177" level="4"><display>(Z)</display>Psilocyn;</subsection><subsection ssid="1-null-125" dnum="AA-o" numlevel="1" lineno="196" slineno="1-178" level="4"><display>(AA)</display>Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis <ln numlevel="1" lineno="197" slineno="1-179"/>(cannabis plant), except for marijuana as defined in Subsection <xref depth="3" refnumber="58-37-2">58-37-2</xref><ln numlevel="1" lineno="198" slineno="1-180"/>(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the <ln numlevel="1" lineno="199" slineno="1-181"/>cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic <ln numlevel="1" lineno="200" slineno="1-182"/>substances, derivatives, and their isomers with similar chemical structure and <ln numlevel="1" lineno="201" slineno="1-183"/>pharmacological activity to those substances contained in the plant, such as the <ln numlevel="1" lineno="202" slineno="1-184"/>following: <char set="8" char="8"/>1 cis or trans tetrahydrocannabinol, and their optical isomers <char set="8" char="8"/>6 cis or <ln numlevel="1" lineno="203" slineno="1-185"/>trans tetrahydrocannabinol, and their optical isomers <char set="8" char="8"/>3,4 cis or trans <ln numlevel="1" lineno="204" slineno="1-186"/>tetrahydrocannabinol, and its optical isomers, and since nomenclature of these <ln numlevel="1" lineno="205" slineno="1-187"/>substances is not internationally standardized, compounds of these structures, <ln numlevel="1" lineno="206" slineno="1-188"/>regardless of numerical designation of atomic positions covered;</subsection><subsection ssid="1-null-126" dnum="BB-o" numlevel="1" lineno="207" slineno="1-189" level="4"><display>(BB)</display>Ethylamine analog of phencyclidine, some trade or other names: <ln numlevel="1" lineno="208" slineno="1-190"/>N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, <ln numlevel="1" lineno="209" slineno="1-191"/>N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;</subsection><subsection ssid="1-null-127" dnum="CC-o" numlevel="1" lineno="210" slineno="1-192" level="4"><display>(CC)</display>Pyrrolidine analog of phencyclidine, some trade or other names: <ln numlevel="1" lineno="211" slineno="1-193"/>1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;</subsection><subsection ssid="1-null-128" dnum="DD-o" numlevel="1" lineno="212" slineno="1-194" level="4"><display>(DD)</display>Thiophene analog of phencyclidine, some trade or other names: <ln numlevel="1" lineno="213" slineno="1-195"/>1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, <ln numlevel="1" lineno="214" slineno="1-196"/>TPCP, TCP; and</subsection><subsection ssid="1-null-129" dnum="EE-o" numlevel="1" lineno="215" slineno="1-197" level="4"><display>(EE)</display>1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.</subsection></subsection><subsection ssid="1-null-130" dnum="iv-o" numlevel="1" lineno="216" slineno="1-198" level="3"><display>(iv)</display>Unless specifically excepted or unless listed in another schedule, any material <ln numlevel="1" lineno="217" slineno="1-199"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="218" slineno="1-200"/>substances having a depressant effect on the central nervous system, including its <ln numlevel="1" lineno="219" slineno="1-201"/>salts, isomers, and salts of isomers when the existence of the salts, isomers, and <ln numlevel="1" lineno="220" slineno="1-202"/>salts of isomers is possible within the specific chemical designation:<subsection ssid="1-null-131" dnum="A-o" numlevel="1" lineno="221" slineno="1-203" level="4"><display>(A)</display>Mecloqualone; and</subsection><subsection ssid="1-null-132" dnum="B-o" numlevel="1" lineno="222" slineno="1-204" level="4"><display>(B)</display>Methaqualone.</subsection></subsection><subsection ssid="1-null-133" dnum="v-o" numlevel="1" lineno="223" slineno="1-205" level="3"><display>(v)</display>Any material, compound, mixture, or preparation containing any quantity of the <ln numlevel="1" lineno="224" slineno="1-206"/>following substances having a stimulant effect on the central nervous system, <ln numlevel="1" lineno="225" slineno="1-207"/>including their salts, isomers, and salts of isomers:<subsection ssid="1-null-134" dnum="A-o" numlevel="1" lineno="226" slineno="1-208" level="4"><display>(A)</display>Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; <ln numlevel="1" lineno="227" slineno="1-209"/>or 4,5-dihydro-5-phenyl-2-oxazolamine;</subsection><subsection ssid="1-null-135" dnum="B-o" numlevel="1" lineno="228" slineno="1-210" level="4"><display>(B)</display>Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, <ln numlevel="1" lineno="229" slineno="1-211"/>alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;</subsection><subsection ssid="1-null-136" dnum="C-o" numlevel="1" lineno="230" slineno="1-212" level="4"><display>(C)</display>Fenethylline;</subsection><subsection ssid="1-null-137" dnum="D-o" numlevel="1" lineno="231" slineno="1-213" level="4"><display>(D)</display>Methcathinone, some other names: 2-(methylamino)-propiophenone; <ln numlevel="1" lineno="232" slineno="1-214"/>alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; <ln numlevel="1" lineno="233" slineno="1-215"/>alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; <ln numlevel="1" lineno="234" slineno="1-216"/>N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, <ln numlevel="1" lineno="235" slineno="1-217"/>its salts, optical isomers, and salts of optical isomers;</subsection><subsection ssid="1-null-138" dnum="E-o" numlevel="1" lineno="236" slineno="1-218" level="4"><display>(E)</display>(<char set="6" char="1"/>)cis-4-methylaminorex ((<char set="6" char="1"/>)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);</subsection><subsection ssid="1-null-139" dnum="F-o" numlevel="1" lineno="237" slineno="1-219" level="4"><display>(F)</display>N-ethylamphetamine; and</subsection><subsection ssid="1-null-140" dnum="G-o" numlevel="1" lineno="238" slineno="1-220" level="4"><display>(G)</display>N,N-dimethylamphetamine, also known as <ln numlevel="1" lineno="239" slineno="1-221"/>N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.</subsection></subsection><subsection ssid="1-null-141" dnum="vi-o" numlevel="1" lineno="240" slineno="1-222" level="3"><display>(vi)</display>Any material, compound, mixture, or preparation which contains any quantity of <ln numlevel="1" lineno="241" slineno="1-223"/>the following substances, including their optical isomers, salts, and salts of <ln numlevel="1" lineno="242" slineno="1-224"/>isomers, subject to temporary emergency scheduling:<subsection ssid="1-null-142" dnum="A-o" numlevel="1" lineno="243" slineno="1-225" level="4"><display>(A)</display>N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and</subsection><subsection ssid="1-null-143" dnum="B-o" numlevel="1" lineno="244" slineno="1-226" level="4"><display>(B)</display>N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).</subsection></subsection><subsection ssid="1-null-144" dnum="vii-o" numlevel="1" lineno="245" slineno="1-227" level="3"><display>(vii)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="246" slineno="1-228"/>compound, mixture, or preparation which contains any quantity of gamma <ln numlevel="1" lineno="247" slineno="1-229"/>hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and <ln numlevel="1" lineno="248" slineno="1-230"/>salts of isomers.</subsection></subsection><subsection ssid="1-null-145" dnum="b-o" numlevel="1" lineno="249" slineno="1-231" level="2"><display>(b)</display>Schedule II:<subsection ssid="1-null-146" dnum="i-o" numlevel="1" lineno="250" slineno="1-232" level="3"><display>(i)</display>Unless specifically excepted or unless listed in another schedule, any of the <ln numlevel="1" lineno="251" slineno="1-233"/>following substances whether produced directly or indirectly by extraction from <ln numlevel="1" lineno="252" slineno="1-234"/>substances of vegetable origin, or independently by means of chemical synthesis, <ln numlevel="1" lineno="253" slineno="1-235"/>or by a combination of extraction and chemical synthesis:<subsection ssid="1-null-147" dnum="A-o" numlevel="1" lineno="254" slineno="1-236" level="4"><display>(A)</display>Opium and opiate, and any salt, compound, derivative, or preparation of <ln numlevel="1" lineno="255" slineno="1-237"/>opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, <ln numlevel="1" lineno="256" slineno="1-238"/>naloxone, and naltrexone, and their respective salts, but including:<subsection ssid="1-null-148" dnum="I-o" numlevel="1" lineno="257" slineno="1-239" level="5"><display>(I)</display>Raw opium;</subsection><subsection ssid="1-null-149" dnum="II-o" numlevel="1" lineno="258" slineno="1-240" level="5"><display>(II)</display>Opium extracts;</subsection><subsection ssid="1-null-150" dnum="III-o" numlevel="1" lineno="259" slineno="1-241" level="5"><display>(III)</display>Opium fluid;</subsection><subsection ssid="1-null-151" dnum="IV-o" numlevel="1" lineno="260" slineno="1-242" level="5"><display>(IV)</display>Powdered opium;</subsection><subsection ssid="1-null-152" dnum="V-o" numlevel="1" lineno="261" slineno="1-243" level="5"><display>(V)</display>Granulated opium;</subsection><subsection ssid="1-null-153" dnum="VI-o" numlevel="1" lineno="262" slineno="1-244" level="5"><display>(VI)</display>Tincture of opium;</subsection><subsection ssid="1-null-154" dnum="VII-o" numlevel="1" lineno="263" slineno="1-245" level="5"><display>(VII)</display>Codeine;</subsection><subsection ssid="1-null-155" dnum="VIII-o" numlevel="1" lineno="264" slineno="1-246" level="5"><display>(VIII)</display>Ethylmorphine;</subsection><subsection ssid="1-null-156" dnum="IX-o" numlevel="1" lineno="265" slineno="1-247" level="5"><display>(IX)</display>Etorphine hydrochloride;</subsection><subsection ssid="1-null-157" dnum="X-o" numlevel="1" lineno="266" slineno="1-248" level="5"><display>(X)</display>Hydrocodone;</subsection><subsection ssid="1-null-158" dnum="XI-o" numlevel="1" lineno="267" slineno="1-249" level="5"><display>(XI)</display>Hydromorphone;</subsection><subsection ssid="1-null-159" dnum="XII-o" numlevel="1" lineno="268" slineno="1-250" level="5"><display>(XII)</display>Metopon;</subsection><subsection ssid="1-null-160" dnum="XIII-o" numlevel="1" lineno="269" slineno="1-251" level="5"><display>(XIII)</display>Morphine;</subsection><subsection ssid="1-null-161" dnum="XIV-o" numlevel="1" lineno="270" slineno="1-252" level="5"><display>(XIV)</display>Oxycodone;</subsection><subsection ssid="1-null-162" dnum="XV-o" numlevel="1" lineno="271" slineno="1-253" level="5"><display>(XV)</display>Oxymorphone; and</subsection><subsection ssid="1-null-163" dnum="XVI-o" numlevel="1" lineno="272" slineno="1-254" level="5"><display>(XVI)</display>Thebaine;</subsection></subsection><subsection ssid="1-null-164" dnum="B-o" numlevel="1" lineno="273" slineno="1-255" level="4"><display>(B)</display>Any salt, compound, derivative, or preparation which is chemically equivalent <ln numlevel="1" lineno="274" slineno="1-256"/>or identical with any of the substances referred to in Subsection <xref depth="4" refnumber="58-37-4(2)(b)(i)(a)">(2)(b)(i)(A)</xref>, <ln numlevel="1" lineno="275" slineno="1-257"/>except that these substances may not include the isoquinoline alkaloids of <ln numlevel="1" lineno="276" slineno="1-258"/>opium;</subsection><subsection ssid="1-null-165" dnum="C-o" numlevel="1" lineno="277" slineno="1-259" level="4"><display>(C)</display>Opium poppy and poppy straw;</subsection><subsection ssid="1-null-166" dnum="D-o" numlevel="1" lineno="278" slineno="1-260" level="4"><display>(D)</display>Coca leaves and any salt, compound, derivative, or preparation of coca leaves, <ln numlevel="1" lineno="279" slineno="1-261"/>and any salt, compound, derivative, or preparation which is chemically <ln numlevel="1" lineno="280" slineno="1-262"/>equivalent or identical with any of these substances, and includes cocaine and <ln numlevel="1" lineno="281" slineno="1-263"/>ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, <ln numlevel="1" lineno="282" slineno="1-264"/>whether derived from the coca plant or synthetically produced, except the <ln numlevel="1" lineno="283" slineno="1-265"/>substances may not include decocainized coca leaves or extraction of coca <ln numlevel="1" lineno="284" slineno="1-266"/>leaves, which extractions do not contain cocaine or ecgonine; and</subsection><subsection ssid="1-null-167" dnum="E-o" numlevel="1" lineno="285" slineno="1-267" level="4"><display>(E)</display>Concentrate of poppy straw, which means the crude extract of poppy straw in <ln numlevel="1" lineno="286" slineno="1-268"/>either liquid, solid, or powder form which contains the phenanthrene alkaloids <ln numlevel="1" lineno="287" slineno="1-269"/>of the opium poppy.</subsection></subsection><subsection ssid="1-null-168" dnum="ii-o" numlevel="1" lineno="288" slineno="1-270" level="3"><display>(ii)</display>Unless specifically excepted or unless listed in another schedule, any of the <ln numlevel="1" lineno="289" slineno="1-271"/>following opiates, including their isomers, esters, ethers, salts, and salts of <ln numlevel="1" lineno="290" slineno="1-272"/>isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and <ln numlevel="1" lineno="291" slineno="1-273"/>salts is possible within the specific chemical designation, except dextrorphan and <ln numlevel="1" lineno="292" slineno="1-274"/>levopropoxyphene:<subsection ssid="1-null-169" dnum="A-o" numlevel="1" lineno="293" slineno="1-275" level="4"><display>(A)</display>Alfentanil;</subsection><subsection ssid="1-null-170" dnum="B-o" numlevel="1" lineno="294" slineno="1-276" level="4"><display>(B)</display>Alphaprodine;</subsection><subsection ssid="1-null-171" dnum="C-o" numlevel="1" lineno="295" slineno="1-277" level="4"><display>(C)</display>Anileridine;</subsection><subsection ssid="1-null-172" dnum="D-o" numlevel="1" lineno="296" slineno="1-278" level="4"><display>(D)</display>Bezitramide;</subsection><subsection ssid="1-null-173" dnum="E-o" numlevel="1" lineno="297" slineno="1-279" level="4"><display>(E)</display>Bulk dextropropoxyphene (nondosage forms);</subsection><subsection ssid="1-null-174" dnum="F-o" numlevel="1" lineno="298" slineno="1-280" level="4"><display>(F)</display>Carfentanil;</subsection><subsection ssid="1-null-175" dnum="G-o" numlevel="1" lineno="299" slineno="1-281" level="4"><display>(G)</display>Dihydrocodeine;</subsection><subsection ssid="1-null-176" dnum="H-o" numlevel="1" lineno="300" slineno="1-282" level="4"><display>(H)</display>Diphenoxylate;</subsection><subsection ssid="1-null-177" dnum="I-o" numlevel="1" lineno="301" slineno="1-283" level="4"><display>(I)</display>Fentanyl;</subsection><subsection ssid="1-null-178" dnum="J-o" numlevel="1" lineno="302" slineno="1-284" level="4"><display>(J)</display>Isomethadone;</subsection><subsection ssid="1-null-179" dnum="K-o" numlevel="1" lineno="303" slineno="1-285" level="4"><display>(K)</display>Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, <ln numlevel="1" lineno="304" slineno="1-286"/>levomethadyl acetate, or LAAM;</subsection><subsection ssid="1-null-180" dnum="L-o" numlevel="1" lineno="305" slineno="1-287" level="4"><display>(L)</display>Levomethorphan;</subsection><subsection ssid="1-null-181" dnum="M-o" numlevel="1" lineno="306" slineno="1-288" level="4"><display>(M)</display>Levorphanol;</subsection><subsection ssid="1-null-182" dnum="N-o" numlevel="1" lineno="307" slineno="1-289" level="4"><display>(N)</display>Metazocine;</subsection><subsection ssid="1-null-183" dnum="O-o" numlevel="1" lineno="308" slineno="1-290" level="4"><display>(O)</display>Methadone;</subsection><subsection ssid="1-null-184" dnum="P-o" numlevel="1" lineno="309" slineno="1-291" level="4"><display>(P)</display>Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;</subsection><subsection ssid="1-null-185" dnum="Q-o" numlevel="1" lineno="310" slineno="1-292" level="4"><display>(Q)</display>Moramide-Intermediate, 2-methyl-3-morpholino-1, <ln numlevel="1" lineno="311" slineno="1-293"/>1-diphenylpropane-carboxylic acid;</subsection><subsection ssid="1-null-186" dnum="R-o" numlevel="1" lineno="312" slineno="1-294" level="4"><display>(R)</display>Pethidine (meperidine);</subsection><subsection ssid="1-null-187" dnum="S-o" numlevel="1" lineno="313" slineno="1-295" level="4"><display>(S)</display>Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;</subsection><subsection ssid="1-null-188" dnum="T-o" numlevel="1" lineno="314" slineno="1-296" level="4"><display>(T)</display>Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;</subsection><subsection ssid="1-null-189" dnum="U-o" numlevel="1" lineno="315" slineno="1-297" level="4"><display>(U)</display>Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;</subsection><subsection ssid="1-null-190" dnum="V-o" numlevel="1" lineno="316" slineno="1-298" level="4"><display>(V)</display>Phenazocine;</subsection><subsection ssid="1-null-191" dnum="W-o" numlevel="1" lineno="317" slineno="1-299" level="4"><display>(W)</display>Piminodine;</subsection><subsection ssid="1-null-192" dnum="X-o" numlevel="1" lineno="318" slineno="1-300" level="4"><display>(X)</display>Racemethorphan;</subsection><subsection ssid="1-null-193" dnum="Y-o" numlevel="1" lineno="319" slineno="1-301" level="4"><display>(Y)</display>Racemorphan;</subsection><subsection ssid="1-null-194" dnum="Z-o" numlevel="1" lineno="320" slineno="1-302" level="4"><display>(Z)</display>Remifentanil; and</subsection><subsection ssid="1-null-195" dnum="AA-o" numlevel="1" lineno="321" slineno="1-303" level="4"><display>(AA)</display>Sufentanil.</subsection></subsection><subsection ssid="1-null-196" dnum="iii-o" numlevel="1" lineno="322" slineno="1-304" level="3"><display>(iii)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="323" slineno="1-305"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="324" slineno="1-306"/>substances having a stimulant effect on the central nervous system:<subsection ssid="1-null-197" dnum="A-o" numlevel="1" lineno="325" slineno="1-307" level="4"><display>(A)</display>Amphetamine, its salts, optical isomers, and salts of its optical isomers;</subsection><subsection ssid="1-null-198" dnum="B-o" numlevel="1" lineno="326" slineno="1-308" level="4"><display>(B)</display>Methamphetamine, its salts, isomers, and salts of its isomers;</subsection><subsection ssid="1-null-199" dnum="C-o" numlevel="1" lineno="327" slineno="1-309" level="4"><display>(C)</display>Phenmetrazine and its salts; and</subsection><subsection ssid="1-null-200" dnum="D-o" numlevel="1" lineno="328" slineno="1-310" level="4"><display>(D)</display>Methylphenidate.</subsection></subsection><subsection ssid="1-null-201" dnum="iv-o" numlevel="1" lineno="329" slineno="1-311" level="3"><display>(iv)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="330" slineno="1-312"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="331" slineno="1-313"/>substances having a depressant effect on the central nervous system, including its <ln numlevel="1" lineno="332" slineno="1-314"/>salts, isomers, and salts of isomers when the existence of the salts, isomers, and <ln numlevel="1" lineno="333" slineno="1-315"/>salts of isomers is possible within the specific chemical designation:<subsection ssid="1-null-202" dnum="A-o" numlevel="1" lineno="334" slineno="1-316" level="4"><display>(A)</display>Amobarbital;</subsection><subsection ssid="1-null-203" dnum="B-o" numlevel="1" lineno="335" slineno="1-317" level="4"><display>(B)</display>Glutethimide;</subsection><subsection ssid="1-null-204" dnum="C-o" numlevel="1" lineno="336" slineno="1-318" level="4"><display>(C)</display>Pentobarbital;</subsection><subsection ssid="1-null-205" dnum="D-o" numlevel="1" lineno="337" slineno="1-319" level="4"><display>(D)</display>Phencyclidine;</subsection><subsection ssid="1-null-206" dnum="E-o" numlevel="1" lineno="338" slineno="1-320" level="4"><display>(E)</display>Phencyclidine immediate precursors: 1-phenylcyclohexylamine and <ln numlevel="1" lineno="339" slineno="1-321"/>1-piperidinocyclohexanecarbonitrile (PCC); and</subsection><subsection ssid="1-null-207" dnum="F-o" numlevel="1" lineno="340" slineno="1-322" level="4"><display>(F)</display>Secobarbital.</subsection></subsection><subsection ssid="1-null-208" dnum="v-o" numlevel="1" lineno="341" slineno="1-323" level="3" space="false"><display>(v)</display><subsection ssid="1-null-209" dnum="A-o" level="4" placement="sameline"><display>(A)</display>Unless specifically excepted or unless listed in another schedule, any <ln numlevel="1" lineno="342" slineno="1-324"/>material, compound, mixture, or preparation which contains any quantity of <ln numlevel="1" lineno="343" slineno="1-325"/>Phenylacetone.</subsection><subsection ssid="1-null-210" dnum="B-o" numlevel="1" lineno="344" slineno="1-326" level="4"><display>(B)</display>Some of these substances may be known by trade or other names: <ln numlevel="1" lineno="345" slineno="1-327"/>phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.</subsection></subsection><subsection ssid="1-null-211" dnum="vi-o" numlevel="1" lineno="346" slineno="1-328" level="3"><display>(vi)</display>Nabilone, another name for nabilone: (<char set="6" char="1"/><ln numlevel="1" lineno="347" slineno="1-329"/>)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6, <ln numlevel="1" lineno="348" slineno="1-330"/>6-dimethyl-9H-dibenzo[b,d]pyran-9-one.</subsection><subsection ssid="1-null-212" dnum="vii-o" numlevel="1" lineno="349" slineno="1-331" level="3"><display>(vii)</display>A drug product or preparation that contains any component of marijuana, <ln numlevel="1" lineno="350" slineno="1-332"/>including tetrahydrocannabinol, and is approved by the United States Food and <ln numlevel="1" lineno="351" slineno="1-333"/>Drug Administration and scheduled by the Drug Enforcement Administration in <ln numlevel="1" lineno="352" slineno="1-334"/>Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.</subsection></subsection><subsection ssid="1-null-213" dnum="c-o" numlevel="1" lineno="353" slineno="1-335" level="2"><display>(c)</display>Schedule III:<subsection ssid="1-null-214" dnum="i-o" numlevel="1" lineno="354" slineno="1-336" level="3"><display>(i)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="355" slineno="1-337"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="356" slineno="1-338"/>substances having a stimulant effect on the central nervous system, including its <ln numlevel="1" lineno="357" slineno="1-339"/>salts, isomers whether optical, position, or geometric, and salts of the isomers <ln numlevel="1" lineno="358" slineno="1-340"/>when the existence of the salts, isomers, and salts of isomers is possible within the <ln numlevel="1" lineno="359" slineno="1-341"/>specific chemical designation:<subsection ssid="1-null-215" dnum="A-o" numlevel="1" lineno="360" slineno="1-342" level="4"><display>(A)</display>Those compounds, mixtures, or preparations in dosage unit form containing <ln numlevel="1" lineno="361" slineno="1-343"/>any stimulant substances listed in Schedule II, which compounds, mixtures, or <ln numlevel="1" lineno="362" slineno="1-344"/>preparations were listed on August 25, 1971, as excepted compounds under <ln numlevel="1" lineno="363" slineno="1-345"/>Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other <ln numlevel="1" lineno="364" slineno="1-346"/>drug of the quantitive composition shown in that list for those drugs or which <ln numlevel="1" lineno="365" slineno="1-347"/>is the same except that it contains a lesser quantity of controlled substances;</subsection><subsection ssid="1-null-216" dnum="B-o" numlevel="1" lineno="366" slineno="1-348" level="4"><display>(B)</display>Benzphetamine;</subsection><subsection ssid="1-null-217" dnum="C-o" numlevel="1" lineno="367" slineno="1-349" level="4"><display>(C)</display>Chlorphentermine;</subsection><subsection ssid="1-null-218" dnum="D-o" numlevel="1" lineno="368" slineno="1-350" level="4"><display>(D)</display>Clortermine; and</subsection><subsection ssid="1-null-219" dnum="E-o" numlevel="1" lineno="369" slineno="1-351" level="4"><display>(E)</display>Phendimetrazine.</subsection></subsection><subsection ssid="1-null-220" dnum="ii-o" numlevel="1" lineno="370" slineno="1-352" level="3"><display>(ii)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="371" slineno="1-353"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="372" slineno="1-354"/>substances having a depressant effect on the central nervous system:<subsection ssid="1-null-221" dnum="A-o" numlevel="1" lineno="373" slineno="1-355" level="4"><display>(A)</display>Any compound, mixture, or preparation containing amobarbital, secobarbital, <ln numlevel="1" lineno="374" slineno="1-356"/>pentobarbital, or any salt of any of them, and one or more other active <ln numlevel="1" lineno="375" slineno="1-357"/>medicinal ingredients which are not listed in any schedule;</subsection><subsection ssid="1-null-222" dnum="B-o" numlevel="1" lineno="376" slineno="1-358" level="4"><display>(B)</display>Any suppository dosage form containing amobarbital, secobarbital, or <ln numlevel="1" lineno="377" slineno="1-359"/>pentobarbital, or any salt of any of these drugs which is approved by the <amend anum="0" ea="amend" pairid="8" groupid="7" style="1" owner="jchristopherson" level="1" amendtag="both">United <ln numlevel="1" lineno="378" slineno="1-360"/>States </amend>Food and Drug Administration for marketing only as a suppository;</subsection><subsection ssid="1-null-223" dnum="C-o" numlevel="1" lineno="379" slineno="1-361" level="4"><display>(C)</display>Any substance which contains any quantity of a derivative of barbituric acid <ln numlevel="1" lineno="380" slineno="1-362"/>or any salt of any of them;</subsection><subsection ssid="1-null-224" dnum="D-o" numlevel="1" lineno="381" slineno="1-363" level="4"><display>(D)</display>Chlorhexadol;</subsection><subsection ssid="1-null-225" dnum="E-o" numlevel="1" lineno="382" slineno="1-364" level="4"><display>(E)</display>Buprenorphine;</subsection><subsection ssid="1-null-226" dnum="F-o" numlevel="1" lineno="383" slineno="1-365" level="4"><display>(F)</display>Any drug product containing gamma hydroxybutyric acid, including its salts, <ln numlevel="1" lineno="384" slineno="1-366"/>isomers, and salts of isomers, for which an application is approved under the <ln numlevel="1" lineno="385" slineno="1-367"/>federal Food, Drug, and Cosmetic Act, Section 505;</subsection><subsection ssid="1-null-227" dnum="G-o" numlevel="1" lineno="386" slineno="1-368" level="4"><display>(G)</display>Ketamine, its salts, isomers, and salts of isomers, some other names for <ln numlevel="1" lineno="387" slineno="1-369"/>ketamine: <char set="6" char="1"/> -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;</subsection><subsection ssid="1-null-228" dnum="H-o" numlevel="1" lineno="388" slineno="1-370" level="4"><display>(H)</display>Lysergic acid;</subsection><subsection ssid="1-null-229" dnum="I-o" numlevel="1" lineno="389" slineno="1-371" level="4"><display>(I)</display>Lysergic acid amide;</subsection><subsection ssid="1-null-230" dnum="J-o" numlevel="1" lineno="390" slineno="1-372" level="4"><display>(J)</display>Methyprylon;</subsection><subsection ssid="1-null-231" dnum="K-o" numlevel="1" lineno="391" slineno="1-373" level="4"><display>(K)</display>Sulfondiethylmethane;</subsection><subsection ssid="1-null-232" dnum="L-o" numlevel="1" lineno="392" slineno="1-374" level="4"><display>(L)</display>Sulfonethylmethane;</subsection><subsection ssid="1-null-233" dnum="M-o" numlevel="1" lineno="393" slineno="1-375" level="4"><display>(M)</display>Sulfonmethane; and</subsection><subsection ssid="1-null-234" dnum="N-o" numlevel="1" lineno="394" slineno="1-376" level="4"><display>(N)</display>Tiletamine and zolazepam or any of their salts, some trade or other names for <ln numlevel="1" lineno="395" slineno="1-377"/>a tiletamine-zolazepam combination product: Telazol, some trade or other <ln numlevel="1" lineno="396" slineno="1-378"/>names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade <ln numlevel="1" lineno="397" slineno="1-379"/>or other names for zolazepam: <ln numlevel="1" lineno="398" slineno="1-380"/>4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] <ln numlevel="1" lineno="399" slineno="1-381"/>[1,4]-diazepin-7(1H)-one, flupyrazapon.</subsection></subsection><subsection ssid="1-null-235" dnum="iii-o" numlevel="1" lineno="400" slineno="1-382" level="3"><display>(iii)</display>Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in <ln numlevel="1" lineno="401" slineno="1-383"/>a U.S. Food and Drug Administration approved drug product, some other names <ln numlevel="1" lineno="402" slineno="1-384"/>for dronabinol: <ln numlevel="1" lineno="403" slineno="1-385"/>(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, <ln numlevel="1" lineno="404" slineno="1-386"/>or (-)-delta-9-(trans)-tetrahydrocannabinol.</subsection><subsection ssid="1-null-236" dnum="iv-o" numlevel="1" lineno="405" slineno="1-387" level="3"><display>(iv)</display>Nalorphine.</subsection><subsection ssid="1-null-237" dnum="v-o" numlevel="1" lineno="406" slineno="1-388" level="3"><display>(v)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="407" slineno="1-389"/>compound, mixture, or preparation containing limited quantities of any of the <ln numlevel="1" lineno="408" slineno="1-390"/>following narcotic drugs, or their salts calculated as the free anhydrous base or <ln numlevel="1" lineno="409" slineno="1-391"/>alkaloid:<subsection ssid="1-null-238" dnum="A-o" numlevel="1" lineno="410" slineno="1-392" level="4"><display>(A)</display>Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 <ln numlevel="1" lineno="411" slineno="1-393"/>milligrams per dosage unit, with an equal or greater quantity of an isoquinoline <ln numlevel="1" lineno="412" slineno="1-394"/>alkaloid of opium;</subsection><subsection ssid="1-null-239" dnum="B-o" numlevel="1" lineno="413" slineno="1-395" level="4"><display>(B)</display>Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 <ln numlevel="1" lineno="414" slineno="1-396"/>milligrams per dosage unit, with one or more active non-narcotic ingredients in <ln numlevel="1" lineno="415" slineno="1-397"/>recognized therapeutic amounts;</subsection><subsection ssid="1-null-240" dnum="C-o" numlevel="1" lineno="416" slineno="1-398" level="4"><display>(C)</display>Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not <ln numlevel="1" lineno="417" slineno="1-399"/>more than 15 milligrams per dosage unit, with a fourfold or greater quantity of <ln numlevel="1" lineno="418" slineno="1-400"/>an isoquinoline alkaloid of opium;</subsection><subsection ssid="1-null-241" dnum="D-o" numlevel="1" lineno="419" slineno="1-401" level="4"><display>(D)</display>Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not <ln numlevel="1" lineno="420" slineno="1-402"/>more than 15 milligrams per dosage unit, with one or more active, non-narcotic <ln numlevel="1" lineno="421" slineno="1-403"/>ingredients in recognized therapeutic amounts;</subsection><subsection ssid="1-null-242" dnum="E-o" numlevel="1" lineno="422" slineno="1-404" level="4"><display>(E)</display>Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more <ln numlevel="1" lineno="423" slineno="1-405"/>than 90 milligrams per dosage unit, with one or more active non-narcotic <ln numlevel="1" lineno="424" slineno="1-406"/>ingredients in recognized therapeutic amounts;</subsection><subsection ssid="1-null-243" dnum="F-o" numlevel="1" lineno="425" slineno="1-407" level="4"><display>(F)</display>Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more <ln numlevel="1" lineno="426" slineno="1-408"/>than 15 milligrams per dosage unit, with one or more active, non-narcotic <ln numlevel="1" lineno="427" slineno="1-409"/>ingredients in recognized therapeutic amounts;</subsection><subsection ssid="1-null-244" dnum="G-o" numlevel="1" lineno="428" slineno="1-410" level="4"><display>(G)</display>Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, <ln numlevel="1" lineno="429" slineno="1-411"/>or not more than 25 milligrams per dosage unit, with one or more active, <ln numlevel="1" lineno="430" slineno="1-412"/>non-narcotic ingredients in recognized therapeutic amounts; and</subsection><subsection ssid="1-null-245" dnum="H-o" numlevel="1" lineno="431" slineno="1-413" level="4"><display>(H)</display>Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams <ln numlevel="1" lineno="432" slineno="1-414"/>with one or more active, non-narcotic ingredients in recognized therapeutic <ln numlevel="1" lineno="433" slineno="1-415"/>amounts.</subsection></subsection><subsection ssid="1-null-246" dnum="vi-o" numlevel="1" lineno="434" slineno="1-416" level="3"><display>(vi)</display>Unless specifically excepted or unless listed in another schedule, anabolic <ln numlevel="1" lineno="435" slineno="1-417"/>steroids including any of the following or any isomer, ester, salt, or derivative of <ln numlevel="1" lineno="436" slineno="1-418"/>the following that promotes muscle growth:<subsection ssid="1-null-247" dnum="A-o" numlevel="1" lineno="437" slineno="1-419" level="4"><display>(A)</display>Boldenone;</subsection><subsection ssid="1-null-248" dnum="B-o" numlevel="1" lineno="438" slineno="1-420" level="4"><display>(B)</display>Chlorotestosterone (4-chlortestosterone);</subsection><subsection ssid="1-null-249" dnum="C-o" numlevel="1" lineno="439" slineno="1-421" level="4"><display>(C)</display>Clostebol;</subsection><subsection ssid="1-null-250" dnum="D-o" numlevel="1" lineno="440" slineno="1-422" level="4"><display>(D)</display>Dehydrochlormethyltestosterone;</subsection><subsection ssid="1-null-251" dnum="E-o" numlevel="1" lineno="441" slineno="1-423" level="4"><display>(E)</display>Dihydrotestosterone (4-dihydrotestosterone);</subsection><subsection ssid="1-null-252" dnum="F-o" numlevel="1" lineno="442" slineno="1-424" level="4"><display>(F)</display>Drostanolone;</subsection><subsection ssid="1-null-253" dnum="G-o" numlevel="1" lineno="443" slineno="1-425" level="4"><display>(G)</display>Ethylestrenol;</subsection><subsection ssid="1-null-254" dnum="H-o" numlevel="1" lineno="444" slineno="1-426" level="4"><display>(H)</display>Fluoxymesterone;</subsection><subsection ssid="1-null-255" dnum="I-o" numlevel="1" lineno="445" slineno="1-427" level="4"><display>(I)</display>Formebulone (formebolone);</subsection><subsection ssid="1-null-256" dnum="J-o" numlevel="1" lineno="446" slineno="1-428" level="4"><display>(J)</display>Mesterolone;</subsection><subsection ssid="1-null-257" dnum="K-o" numlevel="1" lineno="447" slineno="1-429" level="4"><display>(K)</display>Methandienone;</subsection><subsection ssid="1-null-258" dnum="L-o" numlevel="1" lineno="448" slineno="1-430" level="4"><display>(L)</display>Methandranone;</subsection><subsection ssid="1-null-259" dnum="M-o" numlevel="1" lineno="449" slineno="1-431" level="4"><display>(M)</display>Methandriol;</subsection><subsection ssid="1-null-260" dnum="N-o" numlevel="1" lineno="450" slineno="1-432" level="4"><display>(N)</display>Methandrostenolone;</subsection><subsection ssid="1-null-261" dnum="O-o" numlevel="1" lineno="451" slineno="1-433" level="4"><display>(O)</display>Methenolone;</subsection><subsection ssid="1-null-262" dnum="P-o" numlevel="1" lineno="452" slineno="1-434" level="4"><display>(P)</display>Methyltestosterone;</subsection><subsection ssid="1-null-263" dnum="Q-o" numlevel="1" lineno="453" slineno="1-435" level="4"><display>(Q)</display>Mibolerone;</subsection><subsection ssid="1-null-264" dnum="R-o" numlevel="1" lineno="454" slineno="1-436" level="4"><display>(R)</display>Nandrolone;</subsection><subsection ssid="1-null-265" dnum="S-o" numlevel="1" lineno="455" slineno="1-437" level="4"><display>(S)</display>Norethandrolone;</subsection><subsection ssid="1-null-266" dnum="T-o" numlevel="1" lineno="456" slineno="1-438" level="4"><display>(T)</display>Oxandrolone;</subsection><subsection ssid="1-null-267" dnum="U-o" numlevel="1" lineno="457" slineno="1-439" level="4"><display>(U)</display>Oxymesterone;</subsection><subsection ssid="1-null-268" dnum="V-o" numlevel="1" lineno="458" slineno="1-440" level="4"><display>(V)</display>Oxymetholone;</subsection><subsection ssid="1-null-269" dnum="W-o" numlevel="1" lineno="459" slineno="1-441" level="4"><display>(W)</display>Stanolone;</subsection><subsection ssid="1-null-270" dnum="X-o" numlevel="1" lineno="460" slineno="1-442" level="4"><display>(X)</display>Stanozolol;</subsection><subsection ssid="1-null-271" dnum="Y-o" numlevel="1" lineno="461" slineno="1-443" level="4"><display>(Y)</display>Testolactone;</subsection><subsection ssid="1-null-272" dnum="Z-o" numlevel="1" lineno="462" slineno="1-444" level="4"><display>(Z)</display>Testosterone; and</subsection><subsection ssid="1-null-273" dnum="AA-o" numlevel="1" lineno="463" slineno="1-445" level="4"><display>(AA)</display>Trenbolone.</subsection></subsection><subsection ssid="1-null-274" dnum="vii-o" numlevel="1" lineno="464" slineno="1-446" level="3"><display>(vii)</display>Anabolic steroids expressly intended for administration through implants to <ln numlevel="1" lineno="465" slineno="1-447"/>cattle or other nonhuman species, and approved by the Secretary of Health and <ln numlevel="1" lineno="466" slineno="1-448"/>Human Services for use, may not be classified as a controlled substance.</subsection><subsection ssid="1-null-275" dnum="viii-o" numlevel="1" lineno="467" slineno="1-449" level="3"><display>(viii)</display>A drug product or preparation that contains any component of marijuana, <ln numlevel="1" lineno="468" slineno="1-450"/>including tetrahydrocannabinol, and is approved by the United States Food and <ln numlevel="1" lineno="469" slineno="1-451"/>Drug Administration and scheduled by the Drug Enforcement Administration in <ln numlevel="1" lineno="470" slineno="1-452"/>Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.</subsection><subsection ssid="1-null-276" dnum="ix-o" numlevel="1" lineno="471" slineno="1-453" level="3"><display>(ix)</display>Nabiximols.</subsection></subsection><subsection ssid="1-null-277" dnum="d-o" numlevel="1" lineno="472" slineno="1-454" level="2"><display>(d)</display>Schedule IV:<subsection ssid="1-null-278" dnum="i-o" numlevel="1" lineno="473" slineno="1-455" level="3"><display>(i)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="474" slineno="1-456"/>compound, mixture, or preparation containing not more than 1 milligram of <ln numlevel="1" lineno="475" slineno="1-457"/>difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or <ln numlevel="1" lineno="476" slineno="1-458"/>any salts of any of them.</subsection><subsection ssid="1-null-279" dnum="ii-o" numlevel="1" lineno="477" slineno="1-459" level="3"><display>(ii)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="478" slineno="1-460"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="479" slineno="1-461"/>substances, including its salts, isomers, and salts of isomers when the existence of <ln numlevel="1" lineno="480" slineno="1-462"/>the salts, isomers, and salts of isomers is possible within the specific chemical <ln numlevel="1" lineno="481" slineno="1-463"/>designation:<subsection ssid="1-null-280" dnum="A-o" numlevel="1" lineno="482" slineno="1-464" level="4"><display>(A)</display>Alprazolam;</subsection><subsection ssid="1-null-281" dnum="B-o" numlevel="1" lineno="483" slineno="1-465" level="4"><display>(B)</display>Barbital;</subsection><subsection ssid="1-null-282" dnum="C-o" numlevel="1" lineno="484" slineno="1-466" level="4"><display>(C)</display>Bromazepam;</subsection><subsection ssid="1-null-283" dnum="D-o" numlevel="1" lineno="485" slineno="1-467" level="4"><display>(D)</display>Butorphanol;</subsection><subsection ssid="1-null-284" dnum="E-o" numlevel="1" lineno="486" slineno="1-468" level="4"><display>(E)</display>Camazepam;</subsection><subsection ssid="1-null-285" dnum="F-o" numlevel="1" lineno="487" slineno="1-469" level="4"><display>(F)</display>Carisoprodol;</subsection><subsection ssid="1-null-286" dnum="G-o" numlevel="1" lineno="488" slineno="1-470" level="4"><display>(G)</display>Chloral betaine;</subsection><subsection ssid="1-null-287" dnum="H-o" numlevel="1" lineno="489" slineno="1-471" level="4"><display>(H)</display>Chloral hydrate;</subsection><subsection ssid="1-null-288" dnum="I-o" numlevel="1" lineno="490" slineno="1-472" level="4"><display>(I)</display>Chlordiazepoxide;</subsection><subsection ssid="1-null-289" dnum="J-o" numlevel="1" lineno="491" slineno="1-473" level="4"><display>(J)</display>Clobazam;</subsection><subsection ssid="1-null-290" dnum="K-o" numlevel="1" lineno="492" slineno="1-474" level="4"><display>(K)</display>Clonazepam;</subsection><subsection ssid="1-null-291" dnum="L-o" numlevel="1" lineno="493" slineno="1-475" level="4"><display>(L)</display>Clorazepate;</subsection><subsection ssid="1-null-292" dnum="M-o" numlevel="1" lineno="494" slineno="1-476" level="4"><display>(M)</display>Clotiazepam;</subsection><subsection ssid="1-null-293" dnum="N-o" numlevel="1" lineno="495" slineno="1-477" level="4"><display>(N)</display>Cloxazolam;</subsection><subsection ssid="1-null-294" dnum="O-o" numlevel="1" lineno="496" slineno="1-478" level="4"><display>(O)</display>Delorazepam;</subsection><subsection ssid="1-null-295" dnum="P-o" numlevel="1" lineno="497" slineno="1-479" level="4"><display>(P)</display>Diazepam;</subsection><subsection ssid="1-null-296" dnum="Q-o" numlevel="1" lineno="498" slineno="1-480" level="4"><display>(Q)</display>Dichloralphenazone;</subsection><subsection ssid="1-null-297" dnum="R-o" numlevel="1" lineno="499" slineno="1-481" level="4"><display>(R)</display>Estazolam;</subsection><subsection ssid="1-null-298" dnum="S-o" numlevel="1" lineno="500" slineno="1-482" level="4"><display>(S)</display>Ethchlorvynol;</subsection><subsection ssid="1-null-299" dnum="T-o" numlevel="1" lineno="501" slineno="1-483" level="4"><display>(T)</display>Ethinamate;</subsection><subsection ssid="1-null-300" dnum="U-o" numlevel="1" lineno="502" slineno="1-484" level="4"><display>(U)</display>Ethyl loflazepate;</subsection><subsection ssid="1-null-301" dnum="V-o" numlevel="1" lineno="503" slineno="1-485" level="4"><display>(V)</display>Fludiazepam;</subsection><subsection ssid="1-null-302" dnum="W-o" numlevel="1" lineno="504" slineno="1-486" level="4"><display>(W)</display>Flunitrazepam;</subsection><subsection ssid="1-null-303" dnum="X-o" numlevel="1" lineno="505" slineno="1-487" level="4"><display>(X)</display>Flurazepam;</subsection><subsection ssid="1-null-304" dnum="Y-o" numlevel="1" lineno="506" slineno="1-488" level="4"><display>(Y)</display>Halazepam;</subsection><subsection ssid="1-null-305" dnum="Z-o" numlevel="1" lineno="507" slineno="1-489" level="4"><display>(Z)</display>Haloxazolam;</subsection><subsection ssid="1-null-306" dnum="AA-o" numlevel="1" lineno="508" slineno="1-490" level="4"><display>(AA)</display>Ketazolam;</subsection><subsection ssid="1-null-307" dnum="BB-o" numlevel="1" lineno="509" slineno="1-491" level="4"><display>(BB)</display>Loprazolam;</subsection><subsection ssid="1-null-308" dnum="CC-o" numlevel="1" lineno="510" slineno="1-492" level="4"><display>(CC)</display>Lorazepam;</subsection><subsection ssid="1-null-309" dnum="DD-o" numlevel="1" lineno="511" slineno="1-493" level="4"><display>(DD)</display>Lormetazepam;</subsection><subsection ssid="1-null-310" dnum="EE-o" numlevel="1" lineno="512" slineno="1-494" level="4"><display>(EE)</display>Mebutamate;</subsection><subsection ssid="1-null-311" dnum="FF-o" numlevel="1" lineno="513" slineno="1-495" level="4"><display>(FF)</display>Medazepam;</subsection><subsection ssid="1-null-312" dnum="GG-o" numlevel="1" lineno="514" slineno="1-496" level="4"><display>(GG)</display>Meprobamate;</subsection><subsection ssid="1-null-313" dnum="HH-o" numlevel="1" lineno="515" slineno="1-497" level="4"><display>(HH)</display>Methohexital;</subsection><subsection ssid="1-null-314" dnum="II-o" numlevel="1" lineno="516" slineno="1-498" level="4"><display>(II)</display>Methylphenobarbital (mephobarbital);</subsection><subsection ssid="1-null-315" dnum="JJ-o" numlevel="1" lineno="517" slineno="1-499" level="4"><display>(JJ)</display>Midazolam;</subsection><subsection ssid="1-null-316" dnum="KK-o" numlevel="1" lineno="518" slineno="1-500" level="4"><display>(KK)</display>Nimetazepam;</subsection><subsection ssid="1-null-317" dnum="LL-o" numlevel="1" lineno="519" slineno="1-501" level="4"><display>(LL)</display>Nitrazepam;</subsection><subsection ssid="1-null-318" dnum="MM-o" numlevel="1" lineno="520" slineno="1-502" level="4"><display>(MM)</display>Nordiazepam;</subsection><subsection ssid="1-null-319" dnum="NN-o" numlevel="1" lineno="521" slineno="1-503" level="4"><display>(NN)</display>Oxazepam;</subsection><subsection ssid="1-null-320" dnum="OO-o" numlevel="1" lineno="522" slineno="1-504" level="4"><display>(OO)</display>Oxazolam;</subsection><subsection ssid="1-null-321" dnum="PP-o" numlevel="1" lineno="523" slineno="1-505" level="4"><display>(PP)</display>Paraldehyde;</subsection><subsection ssid="1-null-322" dnum="QQ-o" numlevel="1" lineno="524" slineno="1-506" level="4"><display>(QQ)</display>Pentazocine;</subsection><subsection ssid="1-null-323" dnum="RR-o" numlevel="1" lineno="525" slineno="1-507" level="4"><display>(RR)</display>Petrichloral;</subsection><subsection ssid="1-null-324" dnum="SS-o" numlevel="1" lineno="526" slineno="1-508" level="4"><display>(SS)</display>Phenobarbital;</subsection><subsection ssid="1-null-325" dnum="TT-o" numlevel="1" lineno="527" slineno="1-509" level="4"><display>(TT)</display>Pinazepam;</subsection><subsection ssid="1-null-326" dnum="UU-o" numlevel="1" lineno="528" slineno="1-510" level="4"><display>(UU)</display>Prazepam;</subsection><subsection ssid="1-null-327" dnum="VV-o" numlevel="1" lineno="529" slineno="1-511" level="4"><display>(VV)</display>Quazepam;</subsection><subsection ssid="1-null-328" dnum="WW-o" numlevel="1" lineno="530" slineno="1-512" level="4"><display>(WW)</display>Temazepam;</subsection><subsection ssid="1-null-329" dnum="XX-o" numlevel="1" lineno="531" slineno="1-513" level="4"><display>(XX)</display>Tetrazepam;</subsection><subsection ssid="1-null-330" dnum="YY-o" numlevel="1" lineno="532" slineno="1-514" level="4"><display>(YY)</display>Tramadol;</subsection><subsection ssid="1-null-331" dnum="ZZ-o" numlevel="1" lineno="533" slineno="1-515" level="4"><display>(ZZ)</display>Triazolam;</subsection><subsection ssid="1-null-332" dnum="AAA-o" numlevel="1" lineno="534" slineno="1-516" level="4"><display>(AAA)</display>Zaleplon; and</subsection><subsection ssid="1-null-333" dnum="BBB-o" numlevel="1" lineno="535" slineno="1-517" level="4"><display>(BBB)</display>Zolpidem.</subsection></subsection><subsection ssid="1-null-334" dnum="iii-o" numlevel="1" lineno="536" slineno="1-518" level="3"><display>(iii)</display>Any material, compound, mixture, or preparation of fenfluramine which contains <ln numlevel="1" lineno="537" slineno="1-519"/>any quantity of the following substances, including its salts, isomers whether <ln numlevel="1" lineno="538" slineno="1-520"/>optical, position, or geometric, and salts of the isomers when the existence of the <ln numlevel="1" lineno="539" slineno="1-521"/>salts, isomers, and salts of isomers is possible.</subsection><subsection ssid="1-null-335" dnum="iv-o" numlevel="1" lineno="540" slineno="1-522" level="3"><display>(iv)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="541" slineno="1-523"/>compound, mixture, or preparation which contains any quantity of the following <ln numlevel="1" lineno="542" slineno="1-524"/>substances having a stimulant effect on the central nervous system, including its <ln numlevel="1" lineno="543" slineno="1-525"/>salts, isomers whether optical, position, or geometric isomers, and salts of the <ln numlevel="1" lineno="544" slineno="1-526"/>isomers when the existence of the salts, isomers, and salts of isomers is possible <ln numlevel="1" lineno="545" slineno="1-527"/>within the specific chemical designation:<subsection ssid="1-null-336" dnum="A-o" numlevel="1" lineno="546" slineno="1-528" level="4"><display>(A)</display>Cathine ((+)-norpseudoephedrine);</subsection><subsection ssid="1-null-337" dnum="B-o" numlevel="1" lineno="547" slineno="1-529" level="4"><display>(B)</display>Diethylpropion;</subsection><subsection ssid="1-null-338" dnum="C-o" numlevel="1" lineno="548" slineno="1-530" level="4"><display>(C)</display>Fencamfamine;</subsection><subsection ssid="1-null-339" dnum="D-o" numlevel="1" lineno="549" slineno="1-531" level="4"><display>(D)</display>Fenproprex;</subsection><subsection ssid="1-null-340" dnum="E-o" numlevel="1" lineno="550" slineno="1-532" level="4"><display>(E)</display>Mazindol;</subsection><subsection ssid="1-null-341" dnum="F-o" numlevel="1" lineno="551" slineno="1-533" level="4"><display>(F)</display>Mefenorex;</subsection><subsection ssid="1-null-342" dnum="G-o" numlevel="1" lineno="552" slineno="1-534" level="4"><display>(G)</display>Modafinil;</subsection><subsection ssid="1-null-343" dnum="H-o" numlevel="1" lineno="553" slineno="1-535" level="4"><display>(H)</display>Pemoline, including organometallic complexes and chelates thereof;</subsection><subsection ssid="1-null-344" dnum="I-o" numlevel="1" lineno="554" slineno="1-536" level="4"><display>(I)</display>Phentermine;</subsection><subsection ssid="1-null-345" dnum="J-o" numlevel="1" lineno="555" slineno="1-537" level="4"><display>(J)</display>Pipradrol;</subsection><subsection ssid="1-null-346" dnum="K-o" numlevel="1" lineno="556" slineno="1-538" level="4"><display>(K)</display>Sibutramine; and</subsection><subsection ssid="1-null-347" dnum="L-o" numlevel="1" lineno="557" slineno="1-539" level="4"><display>(L)</display>SPA ((-)-1-dimethylamino-1,2-diphenylethane).</subsection></subsection><subsection ssid="1-null-348" dnum="v-o" numlevel="1" lineno="558" slineno="1-540" level="3"><display>(v)</display>Unless specifically excepted or unless listed in another schedule, any material, <ln numlevel="1" lineno="559" slineno="1-541"/>compound, mixture, or preparation which contains any quantity of <ln numlevel="1" lineno="560" slineno="1-542"/>dextropropoxyphene (alpha-(+)-4-dimethylamino-1, <ln numlevel="1" lineno="561" slineno="1-543"/>2-diphenyl-3-methyl-2-propionoxybutane), including its salts.</subsection><subsection ssid="1-null-349" dnum="vi-o" numlevel="1" lineno="562" slineno="1-544" level="3"><display>(vi)</display>A drug product or preparation that contains any component of marijuana and is <ln numlevel="1" lineno="563" slineno="1-545"/>approved by the United States Food and Drug Administration and scheduled by <ln numlevel="1" lineno="564" slineno="1-546"/>the Drug Enforcement Administration in Schedule IV of the federal Controlled <ln numlevel="1" lineno="565" slineno="1-547"/>Substances Act, Title II, P.L. 91-513.</subsection></subsection><subsection ssid="1-null-350" dnum="e-o" numlevel="1" lineno="566" slineno="1-548" level="2"><display>(e)</display>Schedule V:<subsection ssid="1-null-351" dnum="i-o" numlevel="1" lineno="567" slineno="1-549" level="3"><display>(i)</display>Any compound, mixture, or preparation containing any of the following limited <ln numlevel="1" lineno="568" slineno="1-550"/>quantities of narcotic drugs, or their salts calculated as the free anhydrous base or <ln numlevel="1" lineno="569" slineno="1-551"/>alkaloid, which includes one or more non-narcotic active medicinal ingredients in <ln numlevel="1" lineno="570" slineno="1-552"/>sufficient proportion to confer upon the compound, mixture, or preparation <ln numlevel="1" lineno="571" slineno="1-553"/>valuable medicinal qualities other than those possessed by the narcotic drug alone:<subsection ssid="1-null-352" dnum="A-o" numlevel="1" lineno="572" slineno="1-554" level="4"><display>(A)</display>not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;</subsection><subsection ssid="1-null-353" dnum="B-o" numlevel="1" lineno="573" slineno="1-555" level="4"><display>(B)</display>not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 <ln numlevel="1" lineno="574" slineno="1-556"/>grams;</subsection><subsection ssid="1-null-354" dnum="C-o" numlevel="1" lineno="575" slineno="1-557" level="4"><display>(C)</display>not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 <ln numlevel="1" lineno="576" slineno="1-558"/>grams;</subsection><subsection ssid="1-null-355" dnum="D-o" numlevel="1" lineno="577" slineno="1-559" level="4"><display>(D)</display>not more than 2.5 milligrams of diphenoxylate and not less than 25 <ln numlevel="1" lineno="578" slineno="1-560"/>micrograms of atropine sulfate per dosage unit;</subsection><subsection ssid="1-null-356" dnum="E-o" numlevel="1" lineno="579" slineno="1-561" level="4"><display>(E)</display>not more than 100 milligrams of opium per 100 milliliters or per 100 grams;</subsection><subsection ssid="1-null-357" dnum="F-o" numlevel="1" lineno="580" slineno="1-562" level="4"><display>(F)</display>not more than 0.5 milligram of difenoxin and not less than 25 micrograms of <ln numlevel="1" lineno="581" slineno="1-563"/>atropine sulfate per dosage unit; and</subsection><subsection ssid="1-null-358" dnum="G-o" numlevel="1" lineno="582" slineno="1-564" level="4"><display>(G)</display>unless specifically exempted or excluded or unless listed in another schedule, <ln numlevel="1" lineno="583" slineno="1-565"/>any material, compound, mixture, or preparation which contains Pyrovalerone <ln numlevel="1" lineno="584" slineno="1-566"/>having a stimulant effect on the central nervous system, including its salts, <ln numlevel="1" lineno="585" slineno="1-567"/>isomers, and salts of isomers.</subsection></subsection><subsection ssid="1-null-359" dnum="ii-o" numlevel="1" lineno="586" slineno="1-568" level="3"><display>(ii)</display>A drug product or preparation that contains any component of marijuana, <ln numlevel="1" lineno="587" slineno="1-569"/>including cannabidiol, and is approved by the United States Food and Drug <ln numlevel="1" lineno="588" slineno="1-570"/>Administration and scheduled by the Drug Enforcement Administration in <ln numlevel="1" lineno="589" slineno="1-571"/>Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513. </subsection><subsection ssid="1-null-360" dnum="iii-o" numlevel="1" lineno="590" slineno="1-572" level="3"><display>(iii)</display>Gabapentin.</subsection></subsection></subsection><subsection ssid="1-361" dnum="_-o:3-i" numlevel="1" lineno="591" slineno="1-573" ea="amend" anum="0" owner="jchristopherson" style="1" level="1"><display><amend anum="0" ea="amend" pairid="1360" style="1" owner="i" level="1" amendtag="start">(3)</amend></display><amend anum="0" ea="amend" pairid="5" groupid="4" style="1" owner="jchristopherson" level="1" amendtag="end">If the federal government schedules the pharmaceutical composition of a Schedule I <ln numlevel="1" lineno="592" slineno="1-574"/>controlled substance or the pharmaceutical composition of any form of a Schedule I <ln numlevel="1" lineno="593" slineno="1-575"/>controlled substance in a schedule that is not Schedule I, that composition is deemed <ln numlevel="1" lineno="594" slineno="1-576"/>scheduled under this section in the same schedule that the composition is scheduled <ln numlevel="1" lineno="595" slineno="1-577"/>under 21 U.S.C. Sec. 812 and 21 C.F.R. Part 1308.</amend></subsection></section></bsec><bsec buid="2" type="uncod" untype="effdate" src="uncod" uid="EF0000" sort="UZEFF" langlock="true" numlevel="1" lineno="596" slineno="2-1" sn="2"><section type="uncod" untype="effdate" display="false" src="uncod"><secline lineno="596">Section 2.  <bold>Effective Date.</bold></secline><sectionText lineno="597"><amend anum="0" ea="amend" pairid="1" groupid="1" style="1" owner="jchristopherson" level="1" amendtag="both">This bill takes effect on <effdate uid="code" date="5/6/2026">May 6, 2026</effdate>.</amend></sectionText></section></bsec></bdy><foot><rev><tm>1-6-26 12:52 PM</tm></rev></foot></leg>